Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
10.68
-0.04 (-0.37%)
Feb 21, 2025, 4:00 PM EST - Market closed
Roivant Sciences Employees
Roivant Sciences had 908 employees as of March 31, 2024. The number of employees increased by 4 or 0.44% compared to the previous year.
Employees
908
Change (1Y)
4
Growth (1Y)
0.44%
Revenue / Employee
$135,006
Profits / Employee
-$128,437
Market Cap
7.62B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 908 | 4 | 0.44% |
Mar 31, 2023 | 904 | 41 | 4.75% |
Mar 31, 2022 | 863 | 198 | 29.77% |
Jun 30, 2021 | 665 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
ROIV News
- 12 days ago - Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update - GlobeNewsWire
- 17 days ago - Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade) - Seeking Alpha
- 19 days ago - Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care - GlobeNewsWire
- 24 days ago - Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025 - GlobeNewsWire
- 5 weeks ago - Scipher Medicine and Roivant Partner to Bring Precision Medicine Insights to Rheumatology Drug Discovery and Development - Business Wire
- 2 months ago - Roivant Sciences: A Biotech Growth Play With Major Ambitions - Seeking Alpha
- 2 months ago - Roivant's lung disease drug fails mid-stage trial - Reuters